Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
Please note that the ANZCTR website will be unavailable from 9am until 12:30pm (AEDT) on Tuesday 17th November for website maintenance.
Please be sure to log out of the system in order to avoid any loss of data. Thank you and apologies for any inconvenience caused.
A database of clinical trials and their results from Australia, New Zealand, and other countries.
account_circle
Log in
to register or update your trial
search
Search for trials
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT04185883
Registration number
NCT04185883
Ethics application status
Date submitted
3/12/2019
Date registered
4/12/2019
Date last updated
22/10/2025
Titles & IDs
Public title
Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Query!
Scientific title
A Phase 1b, Protocol Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Sotorasib Monotherapy and in Combination With Other Anti-cancer Therapies in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
Query!
Additional trial identifiers [1]
0
0
2023-506794-35
Query!
Additional trial identifiers [2]
0
0
20190135
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Related trial records
Query!
Health condition
Health condition(s) studied:
Advanced Solid Tumors
0
0
Query!
Kirsten Rat Sarcoma (KRAS) pG12C Mutation
0
0
Query!
Condition category
Condition code
Intervention/exposure
Study type
Interventional(has expanded access)
Query!
Description of the intervention or exposure
Treatment: Drugs - Sotorasib
Treatment: Drugs - Trametinib
Treatment: Drugs - RMC-4630
Treatment: Drugs - Afatinib
Treatment: Drugs - Pembrolizumab
Treatment: Drugs - Panitumumab
Treatment: Drugs - Carboplatin, pemetrexed, docetaxel, paclitaxel
Treatment: Drugs - Atezolizumab
Treatment: Drugs - Palbociclib
Treatment: Drugs - MVASI® (bevacizumab-awwb)
Treatment: Drugs - TNO155
Treatment: Drugs - IV Chemotherapy (Regimen 1)
Treatment: Drugs - IV Chemotherapy (Regimen 2)
Treatment: Drugs - BI 1701963
Treatment: Drugs - AMG 404
Treatment: Drugs - Everolimus
Experimental: Sotorasib + trametinib + panitumumab - Experimental: Sotorasib + trametinib + panitumumab Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.
* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors.
Experimental: Sotorasib + RMC-4630 - Experimental: Sotorasib + RMC-4630 Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.
* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants, with KRAS p.G12C mutant advanced solid tumors.
Experimental: Sotorasib + afatinib - Experimental: Sotorasib + afatinib Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.
* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer.
Experimental: Sotorasib + panitumumab +/- chemotherapy - Experimental: Sotorasib + panitumumab +/- chemotherapy Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.
* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors.
Experimental: Sotorasib + atezolizumab - Experimental: Sotorasib + atezolizumab Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.
* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer.
Experimental: Sotorasib + carboplatin, pemetrexed, docetaxel, paclitaxel, pembrolizumab - Experimental: Sotorasib + carboplatin, pemetrexed, docetaxel, paclitaxel, pembrolizumab Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer.
* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer.
Experimental: Sotorasib Monotherapy - Experimental: Sotorasib only Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced non-small cell lung cancer with brain metastases.
* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced non-small cell lung cancer with brain metastases.
Experimental: Sotorasib + palbociclib - Experimental: Sotorasib + palbociclib Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor.
* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor.
Experimental: Sotorasib + pembrolizumab - Experimental: Sotorasib + pembrolizumab Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant non small cell lung cancer.
* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS P.G12C mutant non small cell lung cancer.
Experimental: Sotorasib + MVASI® (bevacizumab-awwb)+ Chemotherapy - Experimental: Sotorasib + MVASI® (bevacizumab-awwb)+ chemotherapy Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced colorectal cancer.
* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced colorectal cancer.
Experimental: Sotorasib + TNO155 - Experimental: Sotorasib + TNO155 Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.
* Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors.
Experimental: Sotorasib + BI 1701963 - Experimental: Sotorasib + BI 1701963 Dose Exploration and Dose Expansion
* Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors.
* Upon completion of dose exploration part of the study the dose expansion cohort is for eligible participants with KRAS P.G12C mutant advanced non-small cell lung cancer and advanced colorectal cancer.
Experimental: Sotorasib + AMG 404 - Experimental: Sotorasib + AMG 404 Dose Exploration and Dose Expansion • Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C mutant advanced solid tumors. • Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumors
Experimental: Sotorasib + everolimus - Experimental: Sotorasib + everolimus Dose Exploration and Dose Expansion • Enrollment into the dose exploration cohort is for eligible participants with KRAS P.G12C advanced solid tumor. • Upon completing the dose exploration part of the study, dose expansion may proceed consisting of participants with KRAS p.G12C mutant advanced solid tumor.
Treatment: Drugs: Sotorasib
Sotorasib administered orally as a tablet.
Treatment: Drugs: Trametinib
Trametinib administered orally as a tablet.
Treatment: Drugs: RMC-4630
RMC-4630 administered orally as a capsule.
Treatment: Drugs: Afatinib
afatinib administered orally as a tablet.
Treatment: Drugs: Pembrolizumab
pembrolizumab administered as an intravenous (IV) infusion.
Treatment: Drugs: Panitumumab
Panitumumab administered as an IV infusion.
Treatment: Drugs: Carboplatin, pemetrexed, docetaxel, paclitaxel
Carboplatin, pemetrexed, docetaxel administered as an IV infusion.
Treatment: Drugs: Atezolizumab
Atezolizumab administered as an IV injection.
Treatment: Drugs: Palbociclib
Palbociclib administered orally as a tablet.
Treatment: Drugs: MVASI® (bevacizumab-awwb)
MVASI® (bevacizumab-awwb) administered as an IV infusion.
Treatment: Drugs: TNO155
TNO155 administered orally as a capsule.
Treatment: Drugs: IV Chemotherapy (Regimen 1)
Chemotherapy combination of leucovorin administered as an IV injection, 5-fluorouracil (5-FU) administered as IV bolus injection or IV continuous infusion (depending on dose), and irinotecan administered as IV injection.
Treatment: Drugs: IV Chemotherapy (Regimen 2)
IV chemotherapy combination of leucovorin administered as an IV injection, 5-FU administered as IV bolus injection or IV continuous infusion (depending on dose), and oxaliplatin administered as IV injection.
Treatment: Drugs: BI 1701963
BI 1701963 administered orally
Treatment: Drugs: AMG 404
AMG 404 administered as an IV infusion.
Treatment: Drugs: Everolimus
Everolimus administered orally.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Description of the comparator or control
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Number of Participants with Dose Limiting Toxicities (DLTs)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
12 Months
Query!
Primary outcome [2]
0
0
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
12 Months
Query!
Primary outcome [3]
0
0
Number of Participants with Treatment-related Adverse Events
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
12 Months
Query!
Primary outcome [4]
0
0
Number of Participants with Clinically Significant Changes in Vital Signs
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
12 Months
Query!
Primary outcome [5]
0
0
Number of Participants with Clinically Significant Changes in ECG Measurements
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
12 Months
Query!
Primary outcome [6]
0
0
Number of Participants with Clinically Significant Changes in Laboratory Test Values
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
12 Months
Query!
Secondary outcome [1]
0
0
Maximum Plasma Concentration (Cmax)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
12 Months
Query!
Secondary outcome [2]
0
0
Time to Maximum Plasma Concentration (Tmax)
Query!
Assessment method [2]
0
0
Query!
Timepoint [2]
0
0
12 Months
Query!
Secondary outcome [3]
0
0
Area Under the Plasma Concentration-time Curve (AUC)
Query!
Assessment method [3]
0
0
Query!
Timepoint [3]
0
0
12 Months
Query!
Secondary outcome [4]
0
0
Objective Response Rate
Query!
Assessment method [4]
0
0
Query!
Timepoint [4]
0
0
12 Months
Query!
Secondary outcome [5]
0
0
Disease Control Rate
Query!
Assessment method [5]
0
0
Query!
Timepoint [5]
0
0
12 Months
Query!
Secondary outcome [6]
0
0
Duration of Response
Query!
Assessment method [6]
0
0
Query!
Timepoint [6]
0
0
12 Months
Query!
Secondary outcome [7]
0
0
Progression-free Survival
Query!
Assessment method [7]
0
0
Query!
Timepoint [7]
0
0
12 Months
Query!
Secondary outcome [8]
0
0
Duration of Stable Disease
Query!
Assessment method [8]
0
0
Query!
Timepoint [8]
0
0
12 Months
Query!
Secondary outcome [9]
0
0
Time to Response
Query!
Assessment method [9]
0
0
Query!
Timepoint [9]
0
0
12 Months
Query!
Secondary outcome [10]
0
0
Overall Survival
Query!
Assessment method [10]
0
0
Query!
Timepoint [10]
0
0
12 Months
Query!
Secondary outcome [11]
0
0
Sotorasib + EGFR Inhibitor +/- Chemotherapeutic Regimen Only: Quantification of Plasma Levels
Query!
Assessment method [11]
0
0
Query!
Timepoint [11]
0
0
12 Months
Query!
Secondary outcome [12]
0
0
Sotorasib Monotherapy Only: Intracranial Objective Response Rate
Query!
Assessment method [12]
0
0
Intracranial objective response rate assessed per Response Assessment in Neuro-oncology Brain Metastases (RANO-BM).
Query!
Timepoint [12]
0
0
12 Months
Query!
Secondary outcome [13]
0
0
Sotorasib Monotherapy Only: Intracranial Disease Control Rate
Query!
Assessment method [13]
0
0
Intracranial disease control rate assessed per RANO-BM.
Query!
Timepoint [13]
0
0
12 Months
Query!
Secondary outcome [14]
0
0
Sotorasib Monotherapy Only: Intracranial Duration of Response
Query!
Assessment method [14]
0
0
Intracranial duration of response assessed per RANO-BM.
Query!
Timepoint [14]
0
0
12 Months
Query!
Secondary outcome [15]
0
0
Sotorasib Monotherapy Only: Time to Intracranial Radiation Therapy
Query!
Assessment method [15]
0
0
Query!
Timepoint [15]
0
0
12 Months
Query!
Secondary outcome [16]
0
0
Sotorasib Monotherapy Only: Intracranial Progression-free Survival (PFS)
Query!
Assessment method [16]
0
0
Intracranial PFS assessed per RANO-BM.
Query!
Timepoint [16]
0
0
12 Months
Query!
Secondary outcome [17]
0
0
Sotorasib Monotherapy Only: Non-intracranial Progression-free Survival (PFS)
Query!
Assessment method [17]
0
0
Non-intracranial PFS assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
Query!
Timepoint [17]
0
0
12 Months
Query!
Secondary outcome [18]
0
0
Sotorasib Monotherapy Only: Overall Progression-free Survival (PFS)
Query!
Assessment method [18]
0
0
Overall PFS assessed per RECIST 1.1 and RANO-BM.
Query!
Timepoint [18]
0
0
12 Months
Query!
Secondary outcome [19]
0
0
Sotorasib + TNO155 Only: Best Overall Response
Query!
Assessment method [19]
0
0
Query!
Timepoint [19]
0
0
12 Months
Query!
Secondary outcome [20]
0
0
Sotorasib + Afatinib + Loperamide Only: Number of Participants with Dose Limiting Toxicities (DLTs)
Query!
Assessment method [20]
0
0
Query!
Timepoint [20]
0
0
12 Months
Query!
Secondary outcome [21]
0
0
Sotorasib + Afatinib + Loperamide Only: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Query!
Assessment method [21]
0
0
Query!
Timepoint [21]
0
0
12 Months
Query!
Secondary outcome [22]
0
0
Sotorasib + Afatinib + Loperamide Only: Number of Participants with Treatment-related Adverse Events
Query!
Assessment method [22]
0
0
Query!
Timepoint [22]
0
0
12 Months
Query!
Secondary outcome [23]
0
0
Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in Vital Signs
Query!
Assessment method [23]
0
0
Query!
Timepoint [23]
0
0
12 Months
Query!
Secondary outcome [24]
0
0
Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in ECG Measurements
Query!
Assessment method [24]
0
0
Query!
Timepoint [24]
0
0
12 Months
Query!
Secondary outcome [25]
0
0
Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in Laboratory Test Values
Query!
Assessment method [25]
0
0
Query!
Timepoint [25]
0
0
12 Months
Query!
Eligibility
Key inclusion criteria
* Men or women greater than or equal to 18 years old.
* Pathologically documented, locally-advanced or metastatic malignancy with, KRAS p.G12C mutation identified through molecular testing performed according to in-country requirements. In the United States, this test must be performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
100
Years
Query!
Query!
Sex
Both males and females
Query!
Healthy volunteers
No
Query!
Key exclusion criteria
* Primary brain tumor.
* Spinal cord compression, or untreated, or symptomatic, or active brain metastases, or leptomeningeal disease from non-brain tumors.
* Myocardial infarction within 6 months of study day 1.
* Gastrointestinal (GI) tract disease causing the inability to take oral medication.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Non-randomised trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Other
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Active, not recruiting
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
17/12/2019
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
5/12/2027
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
610
Query!
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,WA
Query!
Recruitment hospital [1]
0
0
Nepean Cancer Centre - Kingswood
Query!
Recruitment hospital [2]
0
0
GenesisCare -North Shore Oncology - St Leonards
Query!
Recruitment hospital [3]
0
0
Icon Cancer Care South Brisbane - South Brisbane
Query!
Recruitment hospital [4]
0
0
The Queen Elizabeth Hospital - Woodville South
Query!
Recruitment hospital [5]
0
0
St John of God Healthcare - Subiaco
Query!
Recruitment postcode(s) [1]
0
0
2747 - Kingswood
Query!
Recruitment postcode(s) [2]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [3]
0
0
4101 - South Brisbane
Query!
Recruitment postcode(s) [4]
0
0
5011 - Woodville South
Query!
Recruitment postcode(s) [5]
0
0
6008 - Subiaco
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Arizona
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
California
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Colorado
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Connecticut
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Maryland
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Michigan
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Missouri
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
New York
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
North Carolina
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Ohio
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Oregon
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Pennsylvania
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
South Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
South Dakota
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Tennessee
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Utah
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Virginia
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Washington
Query!
Country [25]
0
0
Austria
Query!
State/province [25]
0
0
Graz
Query!
Country [26]
0
0
Austria
Query!
State/province [26]
0
0
Salzburg
Query!
Country [27]
0
0
Belgium
Query!
State/province [27]
0
0
Brussels
Query!
Country [28]
0
0
Belgium
Query!
State/province [28]
0
0
Edegem
Query!
Country [29]
0
0
Canada
Query!
State/province [29]
0
0
Quebec
Query!
Country [30]
0
0
Germany
Query!
State/province [30]
0
0
Berlin
Query!
Country [31]
0
0
Germany
Query!
State/province [31]
0
0
Cologne
Query!
Country [32]
0
0
Germany
Query!
State/province [32]
0
0
Dresden
Query!
Country [33]
0
0
Germany
Query!
State/province [33]
0
0
Essen
Query!
Country [34]
0
0
Italy
Query!
State/province [34]
0
0
Milan
Query!
Country [35]
0
0
Italy
Query!
State/province [35]
0
0
Pisa
Query!
Country [36]
0
0
Italy
Query!
State/province [36]
0
0
Verona
Query!
Country [37]
0
0
Japan
Query!
State/province [37]
0
0
Aichi-ken
Query!
Country [38]
0
0
Japan
Query!
State/province [38]
0
0
Chiba
Query!
Country [39]
0
0
Japan
Query!
State/province [39]
0
0
Tokyo
Query!
Country [40]
0
0
Netherlands
Query!
State/province [40]
0
0
Utrecht
Query!
Country [41]
0
0
South Korea
Query!
State/province [41]
0
0
Seoul
Query!
Country [42]
0
0
Spain
Query!
State/province [42]
0
0
Catalonia
Query!
Country [43]
0
0
Spain
Query!
State/province [43]
0
0
Madrid
Query!
Country [44]
0
0
Taiwan
Query!
State/province [44]
0
0
Tainan City
Query!
Country [45]
0
0
Taiwan
Query!
State/province [45]
0
0
Taipei
Query!
Country [46]
0
0
Taiwan
Query!
State/province [46]
0
0
Taoyuan District
Query!
Country [47]
0
0
United Kingdom
Query!
State/province [47]
0
0
London
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Amgen
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Query!
Trial website
https://clinicaltrials.gov/study/NCT04185883
Query!
Trial related presentations / publications
Kuboki Y, Fakih M, Strickler J, Yaeger R, Masuishi T, Kim EJ, Bestvina CM, Kopetz S, Falchook GS, Langer C, Krauss J, Puri S, Cardona P, Chan E, Varrieur T, Mukundan L, Anderson A, Tran Q, Hong DS. Sotorasib with panitumumab in chemotherapy-refractory KRASG12C-mutated colorectal cancer: a phase 1b trial. Nat Med. 2024 Jan;30(1):265-270. doi: 10.1038/s41591-023-02717-6. Epub 2024 Jan 4.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
MD
Query!
Address
0
0
Amgen
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Amgen Call Center
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
866-572-6436
Query!
Fax
0
0
Query!
Email
0
0
[email protected]
Query!
Contact person for scientific queries
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
Query!
What data in particular will be shared?
De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting document/s available: Study protocol, Statistical analysis plan (SAP), Informed consent form (ICF), Clinical study report (CSR)
Query!
When will data be available (start and end dates)?
Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Query!
Available to whom?
Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Query!
Available for what types of analyses?
Query!
How or where can data be obtained?
IPD available at link: http://www.amgen.com/datasharing
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results not provided in
https://clinicaltrials.gov/study/NCT04185883
Download to PDF